What were the main drivers of the revenue increase in the second quarter of 2005?

The primary drivers for the 18% increase in consolidated net sales to $2.5 billion were the strong performance of the Prescription Pharmaceuticals segment, particularly products like REMICADE, NASONEX, and TEMODAR. Additionally, the inclusion of sales from AVELOX and CIPRO, under the agreement with Bayer, and favorable foreign exchange rates contributed to the growth.

What is the impact of the special charges on the company's financial performance?

The company reported significant special charges, totaling $259 million in the second quarter of 2005, largely due to a $250 million increase in litigation reserves related to the Massachusetts investigation. These charges negatively impacted net income, contributing to a net loss available to common shareholders of $70 million for the quarter. For the first six months, special charges amounted to $286 million.

How is the joint venture with Merck for cholesterol drugs performing, and what is its financial impact?

The joint venture with Merck for ZETIA and VYTORIN continues to be a strong performer. Equity income from this partnership more than doubled in the second quarter of 2005 to $170 million and reached $389 million for the first six months. This growth was driven by the U.S. launch of VYTORIN in late 2004 and strong sales of both products, which now hold over 12% of the U.S. cholesterol management market.

What are the significant legal and regulatory issues facing the company?

The company is involved in several significant legal and regulatory matters, including an ongoing investigation by the U.S. Attorney's Office for the District of Massachusetts concerning sales, marketing, and clinical trial practices, for which the company has increased its litigation reserve to $500 million. It also settled an investigation with the U.S. Attorney's Office for the Eastern District of Pennsylvania in 2004 for $291.9 million. Additionally, the company is subject to a consent decree with the FDA regarding manufacturing practices, which requires ongoing compliance efforts.

MRK 10-Q Quarterly Report Q2 FY2005 — Revenue, Net Income, EPS

Summary

Merck & Co., Inc. (MRK) reported its second quarter and first half results for 2005, highlighting significant revenue growth driven by its Prescription Pharmaceuticals segment. The company saw an 18% increase in net sales for the quarter, reaching $2.5 billion, and a 19% increase year-over-year for the first half, totaling $4.9 billion. This growth was boosted by strong performance in key products like REMICADE, NASONEX, and TEMODAR, alongside the initial contributions from the Bayer agreement for antibiotics AVELOX and CIPRO. However, the company's net income available to common shareholders remained in a loss for the quarter ($70 million) and showed a modest gain for the first half ($35 million), largely due to significant special charges. A substantial increase in litigation reserves, particularly for the Massachusetts investigation, contributed $250 million to these charges in the second quarter, leading to total special charges of $286 million for the first half. Operationally, the company is navigating complex challenges, including ongoing legal and regulatory matters. The joint venture with Merck for cholesterol-lowering drugs (ZETIA and VYTORIN) continues to be a significant revenue driver, with equity income from this partnership more than doubling in the second quarter compared to the prior year. Management is focused on its Action Agenda to stabilize and grow the business, despite ongoing R&D investments and the high cost associated with regulatory compliance, such as the FDA consent decree. The company's liquidity is being managed through repatriated foreign earnings and credit facilities, though debt levels and ongoing legal expenses present potential headwinds.

Key Highlights

1Consolidated net sales increased by 18% in Q2 2005 to $2.5 billion and by 19% for the first six months to $4.9 billion, driven by the Prescription Pharmaceuticals segment.
2Equity income from the cholesterol joint venture with Merck more than doubled in Q2 2005 to $170 million and significantly increased for the six-month period to $389 million.
3Significant special charges totaling $259 million in Q2 2005, primarily related to an increase in litigation reserves for the Massachusetts investigation ($250 million), impacting net income.
4Net loss available to common shareholders in Q2 2005 was $70 million, though net income available to common shareholders for the first six months of 2005 was $35 million, a significant improvement from a loss of $138 million in the prior year.
5The company is investing in R&D, with spending at $442 million for Q2 and $825 million for the six-month period, representing 17.4% and 16.8% of net sales, respectively.
6Strong sales growth was observed in key products like NASONEX (+28% in Q2), TEMODAR (+42% in Q2), and international REMICADE sales (+29% in Q2).
7The company is managing liquidity by repatriating previously unremitted foreign earnings under the American Jobs Creation Act of 2004, supplementing its $1.5 billion revolving credit facility.

Merck & Co., Inc. Quarterly Report for Q2 Ended Jun 30, 2005

Summary

Key Highlights

Frequently Asked Questions